Session Information
Date: Wednesday, June 22, 2016
Session Title: Parkinson's disease: Neuroimaging and neurophysiology
Session Time: 12:00pm-1:30pm
Location: Exhibit Hall located in Hall B, Level 2
Objective: We aim to establish the normal reference with quantitative 99mTc-Trodat-1 (TRODAT) SPECT and verify the diagnostic performance in aged Parkinson’s disease (PD) patients.
Background: TRODAT SPECT with low-energy high-resolution (LEHR) collimation has been widely utilized to assess striatal dopamine activity transporter (DAT) for diagnosis of PD in Taiwan. However, its diagnostic performance has not been reported.
Methods: Thirty-seven aged subjects as normal reference (NR) (n=16, 60-82 yrs) and clinically confirmed PD patients (n=21, 61-81, HY stage: 2.6±1.04) were enrolled to receive TRODAT SPECT and MRI scans. The imaging protocol utilizes to image subjects with 3 hrs delay post 30 mCi TRODAT injection. All quantitative SPECT images were reconstructed with full physical corrections and normalized to MRI brain template. DAT parameter as specific binding ratio (SBR) as [(target – background)/background] and left-right SBR symmetry (SBRS) was calculated with MRI voxel-based striatal ROI template. ROC curve analysis was used to assess the diagnostic performance of TRODAT SPEC in aged PD patients.
Results: PD SBR values were significantly lower than those of NR for subjects with 60-69 yrs (group I: 0.52±0.70 vs. 1.06±0.14, p = 0.0002) and > 70yrs (group II: 0.38±0.30 vs. 0.72±0.10, p = 0.0069). ROC curve analysis showed that areas under the curve (AUC) were 0.96 and 0.84 for group I and II, respectively. SBR cut-off, sensitivity and specificity were 0.79, 0.80 and 0.87 for group I; and 0.58, 0.81 and 1.00 for group II. Difference between NR and PD SBRS was slightly larger in group 1 (0.90 vs 0.76, p=0.02) than in group II (0.82 vs 0.72, p=0.22). 
Conclusions: Quantitative TRODAT SPECT with LEHR collimation is an effective approach to provide DAT parameter for diagnosis of patients with aged PD. Future research should be extended to test the performance on PD of younger population (<60 yrs).
To cite this abstract in AMA style:
C.F. Lee, C.Y. Wei, G.U. Huang, I.J. Chen, B. Hsu. The efficacy of quantitative 99mTc-TRODAT-1 SPECT in diagnosis of aged patients with Parkinson’s disease [abstract]. Mov Disord. 2016; 31 (suppl 2). https://www.mdsabstracts.org/abstract/the-efficacy-of-quantitative-99mtc-trodat-1-spect-in-diagnosis-of-aged-patients-with-parkinsons-disease/. Accessed May 18, 2025.« Back to 2016 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/the-efficacy-of-quantitative-99mtc-trodat-1-spect-in-diagnosis-of-aged-patients-with-parkinsons-disease/